Global Diabetic Assays Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Dec 2019
  • Global
  • 350 Pages
  • No of Tables: 321
  • No of Figures: 65

By Type (Assays, Devices, Consumables), Disease Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), Deployment (Automated, Manual), End User (Hospitals, Clinics, Diagnostic Laboratories, Academic Institutes, Others), Distribution Channel (Direct, Indirect), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, South Africa, Rest of Middle East and Africa),Market Trends and  Forecast to 2027.

Market Analysis and Insights: Global Diabetic Assays Market

Global diabetic assays market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with the CAGR of 4.3% in the forecast period of 2020 to 2027and expected to reach USD 4,102.92 million by 2027 from USD 1,832.42 million in 2019. Growing prevalence of diabetes are the factors for the market growth.

Diabetes is one of the most serious endocrine diseases. Almost 425 million people worldwide suffer from this disease. Diabetes mellitus refers to a group of long-term health issues that affect the way blood sugar is used in the body because it cannot produce insulin or respond effectively to that insulin. A significant proportion of diabetics are undiagnosed. There are three types of type 1 diabetes, type 2 diabetes and gestational diabetes. Diabetes tests include tests for glycated hemoglobin (HbA1c), C-peptide tests, blood glucose fasting tests and insulin tests.

Growing prevalence of diabetes and awareness towards it identification among population as compared to the past few years will accelerate the market growth.  

For instance, in 2018, World Health Organization projected that there were 125 million people aged 80 years or older and expected to be 2 billion by the year 2050. Increasing number of cases of diabetes among population and growing the prevalence rate among aged and younger generation due to high obesity rate and cardiovascular diseases leads to high detection of diabetes and leading the growth of diabetes assays market.

This diabetic assays market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Diabetic Assays Market Scope and Market Size

Global diabetic assays market is segmented on the basis of type, disease type, deployment, end- user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into device, assays and consumables. In 2020, the assays segment is dominating and growing with the highest CAGR due to the advancement in the diagnosis procedure which enhances the ability to predict on time diabetes.

The advancement in assays such as quick identification of diabetes through blood samples major vendors augmented to the market growth of diabetes assays market. For instance,     In June 2019, Abbott (U.S.) has launched its first rapid point-of-care HbA1c test to diagnose diabetes “Afinion HbA1c Dx assay” for use on Afinion AS100 Analyzer and Afinion 2 Analyzer. The Afinion HbA1c Dx assay is the first and rapid point-of-care method approved by the U.S. Food and Drug Administration (FDA) to support health professionals in the diagnosis and treatment of diabetes. This launch will expand the product portfolio as well as user base of the company. The government regulations to support health care professionals in diagnosis of diabetes and high utilization of assays by the hospitals, clinics and private laboratories and augmented in market growth.

On the basis of disease type, the market is segmented into type 1 diabetes, type 2 diabetes and gestational diabetes. In 2020, type 2 diabetes segments is dominating and growing in the global diabetic assays market as the occurrence of type 2 diabetes are more which accounts for more than 80% in American population.  

On the basis of deployment, the market is segmented into automated and manual. In 2020, automated segment is dominating and growing with the highest CAGR because of the new development of analysers and associated software which provides automated operational workflow while diagnosis procedure.

On the basis of end user, the market is segmented into hospitals, clinics, diagnostic laboratories, academic institutes and others. In 2020, hospitals segment is dominating as well as growing in the market as the diabetes assays are directly performed in the hospitals.

On the basis of distribution channel, the market is segmented into direct and indirect. In 2020, the direct segment is dominating the diabetic assays market and is growing with the highest CAGR as majority of the assays, analysers and consumables are directly distributed to end users such as hospitals, diagnostic clinics and others.

Diabetic Assays Market Country Level Analysis

Diabetic assays market is analysed and market size information is provided by country, by type, disease type, deployment, end user and distribution channel as referenced above.

The countries covered in the diabetic assays market report are the U.S., Canada and Mexico in North America, Germany, U.K., France, Switzerland, Italy, Spain, Belgium, Netherlands, Poland, Ireland, Austria, Russia, Hungary, Turkey, Lithuania, Norway and rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam and rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, Kuwait, South Africa, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil, Argentina, Peru and Rest of South America as part of South America.

Country Level Analysis, By Type

North America dominates the diabetic assays market as the U.S. is leader in diabetic assays manufacturing and major leaders are generating revenue from U.S. due to high prevalence cases of diabetes in the United States population requires high detection of diabetes assays for the identification and detection of diabetes diseases. For instance, in 2017, United Nation projected that 1 out of 5 diabetes patients are above 65 years old. The growing diabetes cases among geriatric population in U.S. leading the dominance of North America in Assays market.   The Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing emerging economical condition and investment of vendors to develop the diabetes assays leading the Asia-Pacific growth with highest CAGR.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Awareness towards the Detection of Diabetes and New Technology Penetration

Diabetic assays market also provides you with detailed market analysis for every country growth in automotive industry with Diabetic assays sales, components sales, impact of technological development in assays and changes in regulatory scenarios with their support for the diabetic assays market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Diabetic Assays Market Share Analysis

Diabetic assays market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to global diabetic assays market.

The major players covered in the report are Abbott, Danaher, Merck KGaA, SIEMENS HEALTHINEERS AG, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., EKF Diagnostics, DRG INSTRUMENTS GMBH, PTS Diagnostics, Ortho Clinical Diagnostics, Medipan GmbH, Diagnostic Automation/Cortez Diagnostics Inc., Diazyme Laboratories, Inc., Ethos Biosciences, Inc., BioAssay Systems, Tosoh Corporation, Abnova Corporation, Monobind Inc, ORGENTEC Diagnostika GmbH, ALPCO., among other domestic and global players. Diabetic assays market share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product developments are also initiated by the companies worldwide which are also accelerating the global diabetic assays market.

For instance,

  • In June 2019, Abbott (U.S.) has launched its first rapid point-of-care HbA1c test to diagnose diabetes “Afinion HbA1c Dx assay” for use on Afinion AS100 Analyzer and Afinion 2 Analyzer. The Afinion HbA1c Dx assay is the first and rapid point-of-care method approved by the U.S. Food and Drug Administration (FDA) to support health professionals in the diagnosis and treatment of diabetes. This launch will expand the product portfolio as well as user base of the company.
  • In March 2019, Beckman Coulter, Inc, hemoglobin A1c (HbA1c) Advanced assay received CE Mark Certification and the U.S. FDA 501(k) Clearance. Through this achievement, the company will offer initial diagnosis of diabetes and will also deliver the clinically operative outcomes.

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for diabetic assays through expanded model range.

Customization Available : Global Diabetic Assays Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-
CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
BUY NOW ADD TO CART
Why Choose Us
REQUEST FOR SAMPLE